HSBC AM forays into active ETF market with five funds
HSBC Asset Management (HSBC AM) has launched the HSBC PLUS Active ETF range, marking its entry into the active ETF market with five new funds.
This launch aims to provide investors with country and regional exposures, combining the benefits of the ETF wrapper with the potential for outperforming returns, stated the company.
The HSBC PLUS Active ETF range includes the HSBC PLUS USA Equity Quant Active UCITS ETF, HSBC PLUS World Equity Quant Active UCITS ETF, HSBC PLUS Emerging Markets Equity Quant Active UCITS ETF, HSBC PLUS World Equity Income Quant Active UCITS ETF, and HSBC PLUS Emerging Markets Equity Income Quant Active UCITS ETF.
These funds utilise a quantitative-driven investment approach, leveraging HSBC AM's Quantitative Equity capabilities.
The core range, consisting of the HSBC PLUS USA Equity Quant Active UCITS ETF, HSBC PLUS World Equity Quant Active UCITS ETF, and HSBC PLUS Emerging Markets Equity Quant Active UCITS ETF, focuses on maximising exposure to the highest-ranked stocks based on factor characteristics while minimising overall portfolio risk.
The income range aims to identify equity securities with attractive income and quality characteristics, providing additional income compared to a market-cap index while preserving capital growth, added the company.
These funds are available to retail, wholesale, and institutional investors in Austria, Germany, Spain, France, Italy, Luxembourg, Sweden, and the UK. They will also be listed on the London Stock Exchange, Borsa Italiana, and Xetra.
HSBC AM ETF and Indexing Sales global head Olga de Tapia stated, 'The active ETF market is enjoying strong growth, and we are pleased to introduce our suite of funds in this space as part of our efforts to bring innovative and relevant investment tools to investors.'
Tapia further added, 'Our HSBC PLUS Active ETF range combines quantitative active management with the efficiency of an ETF structure and aims to provide investors with additional alpha beyond core passive exposures in a cost-efficient way and ensuring resilience across diverse market cycles and economic regimes.'
Last month, HSBC announced that its group chairman Mark Tucker intends to retire before the end of 2025.
"HSBC AM forays into active ETF market with five funds" was originally created and published by Private Banker International, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
A £10,000 investment in Standard Chartered shares 10 years ago is now worth…
Despite some operational problems, a focus on fast-growing developing regions means Standard Chartered's (LSE:STAN) shares have provided solid returns over the last decade. At £11.56 per share, the FTSE 100 bank has risen 20.3% in value from the 961.3p it traded at 10 years ago. It's an ascent that would have turned a £10,000 lump sum investment back then into a cool £12,028 today. The overall return improves further too, when adding in dividends over the last decade. Since mid-2015, dividends from the business have totalled 109.7p per share. As a consequence, a £10k investment in the bank back then would have produced a total shareholder return of £13,169, or 31.7%. That's not bad, but it's hardly a stunning result. To put that in perspective, the broader Footsie's delivered a return of 82.9% in that timeframe. Fellow emerging market bank HSBC has also delivered better returns over that time. With capital gains and dividends combined, StanChart's Asian rival's total returns stand just above 100%. As I alluded to above, the bank's suffered a number of performance-denting setbacks between 2015 and 2020. Compliance issues resulted in severe reputational damage and heavy financial penalties. It also had to heavily restructure to improve performance and beef up the balance sheet. But with these issues now in the distant past, could Standard Chartered shares deliver better returns from now on? Like any bank, the company's highly sensitive to broader economic conditions. During downturns, profits can slump as demand for financial services declines. At the same time, loan impairments can shoot through the roof. This is a significant danger for the FTSE company as the key Chinese economy splutters, causing wider problems across its Asia Pacific region. Standard Chartered sources around three-quarters of revenue from customers in this territory. Worryingly for the country's banks, China's property sector continues to soften as well. StanChart's been no stranger to substantial real estate-related writedowns in recent years. Established banks like this also face intense competition from digital banks. According to Statista, net interest income among digital-only competitors will grow at an annualised rate of 9.36% between 2025 and 2029. Having said that, Standard Chartered's enjoying its own successes in the digital realm. Its Mox and Trust platforms (in Hong Kong and Singapore, respectively) have enjoyed strong take-up following their launches in recent years. And the bank has significant resources to continue building its presence in this key growth segment. What's more, while Asian banks may suffer some discomfort in the near term, the long-term outlook for the continent remains extremely bright. As with StanChart's African and Middle East markets, there's scope for substantial profits growth as personal wealth levels climb and populations steadily increase. Today, the stock trades on a forward price-to-earnings (P/E) ratio of 8.2 times. It also trades on a sub-1 price-to-earnings growth (PEG) ratio of 0.6. Such readings fail to reflect Standard Chartered's enormous growth potential, in my view. I think it's a top FTSE 100 share to consider right now. The post A £10,000 investment in Standard Chartered shares 10 years ago is now worth… appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool HSBC Holdings is an advertising partner of Motley Fool Money. Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended HSBC Holdings and Standard Chartered Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
14 hours ago
- Bloomberg
Yield Rise After Strong Jobs Report
Sonali Basak highlights the market-moving news you need to know. Today's guests: JPMorgan Asset Management Global FICC US CIO Kay Herr, Invesco Head of Fixed Income Business Strategy and Development Stephanie Larosiliere, HSBC Americas Head of Debt Capital Markets Patrice Altongy, and Barings High Yield Portfolio Manager Michael Best. (Source: Bloomberg)
